Advertisement

Tumor Biology

, Volume 35, Issue 12, pp 12389–12395 | Cite as

Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer

  • Tuulia Vallius
  • Johanna Hynninen
  • Annika Auranen
  • Olli Carpén
  • Jaakko Matomäki
  • Sinikka Oksa
  • Johanna Virtanen
  • Seija Grénman
Research Article

Abstract

Human epididymis protein 4 (HE4) is a novel tumour marker in epithelial ovarian cancer (EOC). Data on its profile and predictive potential for subsequent outcome after neoadjuvant chemotherapy (NACT) are still under investigation. The aim of this study was to compare CA125 and HE4 profiles with radiologic response after NACT and to evaluate their potential as predictors of clinical outcome in a primarily inoperable EOC patient cohort. Twenty-five EOC patients of high-grade subtype (HGSC) treated with NACT were enrolled in the study. Serum HE4 and CA125 samples were taken at the time of diagnosis and before interval debulking surgery (IDS). Pre-NACT and pre-IDS HE4 and CA125 and their percentage changes were compared with NACT response seen on CT and surgical outcome in IDS. We also evaluated the biomarkers’ abilities to predict platinum-free interval (PFI), progression-free survival (PFS) and overall survival (OS). All 25 patients were considered inoperable in laparoscopy at the time of diagnosis. HE4 and CA125 changes during NACT did not correlate with the changes seen on CT. Surgical outcome in IDS was associated with pre-IDS biomarker values but not with those taken before diagnosis. In IDS, 87 % had <1-cm residual tumour. In patients with HE4 change >80 and <80 % during NACT, the median OS was 3.38 and 1.60 years (p = 0.01), respectively. Serum HE4 is a promising additional tool when evaluating advanced HGSC patient’s response to NACT. It may be helpful when deciding whether to proceed to IDS or to second-line chemotherapy.

Keywords

Ovarian high-grade serous cancer Neoadjuvant chemotherapy HE4 CA125 Treatment response Predictive value 

Notes

Acknowledgments

This study was financially supported by the Clinical Research (EVO) funding of Turku University Hospital. We are thankful to Pia Roering for the technical assistance with HE4 analyses.

Conflicts of interest

None.

References

  1. 1.
    Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53.PubMedCrossRefGoogle Scholar
  2. 2.
    Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. Eur J Cancer. 2011;47 Suppl 3:S88–92.PubMedCrossRefGoogle Scholar
  3. 3.
    Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol. 2009;16(8):2315–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59.PubMedCrossRefGoogle Scholar
  5. 5.
    du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234–44.PubMedCrossRefGoogle Scholar
  6. 6.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.PubMedCrossRefGoogle Scholar
  7. 7.
    Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419–23.PubMedCrossRefGoogle Scholar
  8. 8.
    Rodriguez N, Rauh-Hain JA, Shoni M, Berkowitz RS, Muto MG, Feltmate C, et al. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012;125(2):362–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Furukawa N, Sasaki Y, Shigemitsu A, Akasaka J, Kanayama S, Kawaguchi R, et al. CA-125 cut-off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer. J Gynecol Oncol. 2013;24(2):141–5.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Vasudev NS, Trigonis I, Cairns DA, Hall GD, Jackson DP, Broadhead T, et al. The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma. Arch Gynecol Obstet. 2011;284(1):221–7.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Riedinger JM, Wafflart J, Ricolleau G, Eche N, Larbre H, Basuyau JP, et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol. 2006;17(8):1234–8.PubMedCrossRefGoogle Scholar
  12. 12.
    van Altena AM, Kolwijck E, Spanjer MJ, Hendriks JC, Massuger LF, de Hullu JA. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population based study. Gynecol Oncol. 2010;119(2):265–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108(2):402–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100(8):1315–9.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Park Y, Lee JH, Hong DJ, Lee EY, Kim HS. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem. 2011;44(10–11):884–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Angioli R, Capriglione S, Aloisi A, Guzzo F, Luvero D, Miranda A, et al. Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer? Tumour Biol. 2014 Apr 21.Google Scholar
  17. 17.
    Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol. 2010;31(2):113–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Angioli R, Plotti F, Capriglione S, Aloisi A, Montera R, Luvero D, et al. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol. 2013;128(3):579–83.PubMedCrossRefGoogle Scholar
  19. 19.
    Braicu EI, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, et al. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. Gynecol Oncol. 2013;128(2):245–51.PubMedCrossRefGoogle Scholar
  20. 20.
    Fagotti A, Ferrandina G, Fanfani F, Garganese G, Vizzielli G, Carone V, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol. 2008;199:642e1–6.CrossRefGoogle Scholar
  21. 21.
    Menczer J, Usviatzov I, Ben-Shem E, Golan A, Levy T. Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival? J Gynecol Oncol. 2011;22(3):183–7.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2012. ISBN 3-900051-07-0, URL http://www.R-project.org/.
  23. 23.
    Hynninen J, Auranen A, Dean K, Lavonius M, Carpen O, Perheentupa A, et al. Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21(9):1573–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Yildirim Y, Ertas IE, Dogan A, Gultekin OE, Gultekin E. The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer. J Surg Oncol. 2012;105(2):200–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Bellati F, Gasparri ML, Caccetta J, Palaia I, Benedetti Panici P. Response criteria can be misleading when drawing conclusion regarding neoadjuvant chemotherapy in advanced ovarian cancer. J Surg Oncol. 2012;106(4):529. author reply 527-8.PubMedCrossRefGoogle Scholar
  26. 26.
    Tate S, Hirai Y, Takeshima N, Hasumi K. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. J Gynecol Oncol. 2005;96(1):143–9.CrossRefGoogle Scholar
  27. 27.
    Le T, Hopkins L, Faught W, Fung-Kee-Fung M. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Gynecol Oncol. 2007;105(3):712–5.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Tuulia Vallius
    • 1
  • Johanna Hynninen
    • 1
  • Annika Auranen
    • 1
  • Olli Carpén
    • 2
  • Jaakko Matomäki
    • 3
  • Sinikka Oksa
    • 4
  • Johanna Virtanen
    • 5
  • Seija Grénman
    • 1
  1. 1.Department of Obstetrics and Gynecology, Turku University HospitalUniversity of TurkuTurkuFinland
  2. 2.Department of PathologyUniversity of Turku and Turku University HospitalTurkuFinland
  3. 3.Department of Pediatrics, Turku University HospitalUniversity of TurkuTurkuFinland
  4. 4.Department of Obstetrics and GynecologySatakunta Central HospitalPoriFinland
  5. 5.Department of Radiology, Turku University HospitalUniversity of TurkuTurkuFinland

Personalised recommendations